Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Treatment Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT00494572
What this trial is testing

Montelukast With Status Asthmaticus, Ages 6-18

Who this might be right for
Status AsthmaticusAsthma
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390865
What this trial is testing

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 49
Early research (Phase 1)Study completedNCT03309111
What this trial is testing

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA 81
Not applicableStudy completedNCT03485131
What this trial is testing

Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations

Who this might be right for
Auditory HallucinationSchizophrenia
Manhattan Psychiatric Center 27
Not applicableLooking for participantsNCT06111612
What this trial is testing

Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic NeoplasmChronic Myelomonocytic Leukemia+2 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 50
Early research (Phase 1)Study completedNCT00040781
What this trial is testing

Gefitinib in Treating Children With Refractory Solid Tumors

Who this might be right for
Unspecified Childhood Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 45
Not applicableStudy completedNCT02988830
What this trial is testing

Impact of Subcutaneous Electric Lumbar Stimulation on Treatment of Refractory Chronic and Disabling Lumbago

Who this might be right for
Pain
Hopital Foch 19
Early research (Phase 1)WithdrawnNCT06007911
What this trial is testing

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed Adult AMLRefractory AML
Medical College of Wisconsin
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439136
What this trial is testing

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 40
Early research (Phase 1)Active Not RecruitingNCT04608487
What this trial is testing

Axi-cel in CNS Lymphoma

Who this might be right for
LymphomaLymphoma Cns
Dana-Farber Cancer Institute 18
Testing effectiveness (Phase 2)Study completedNCT01369849
What this trial is testing

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) 15
Early research (Phase 1)Study completedNCT00346255
What this trial is testing

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
ImmunoGen, Inc. 37
Testing effectiveness (Phase 2)Study completedNCT00051116
What this trial is testing

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene Corporation 100
Not applicableStudy completedNCT03389347
What this trial is testing

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 40
Testing effectiveness (Phase 2)Looking for participantsNCT06644443
What this trial is testing

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Shenzhen University General Hospital 10
Not applicableStudy completedNCT01167621
What this trial is testing

Changes in Refractory Acute Respiratory Distress Syndrome (ARDS) Patients Under High Frequency Oscillation-ventilation

Who this might be right for
Respiratory Distress Syndrome, Adult
Centre Hospitalier Universitaire de la Réunion 23
Testing effectiveness (Phase 2)Study completedNCT02939014
What this trial is testing

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Who this might be right for
Hodgkin DiseaseLymphoma, Large-Cell, Anaplastic
Takeda 39
Not applicableStudy completedNCT01137955
What this trial is testing

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

Who this might be right for
Celiac Disease
Columbia University 50
Testing effectiveness (Phase 2)Study completedNCT01736943
What this trial is testing

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

Who this might be right for
Acute Myelogenous Leukemia
Joseph Tuscano 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07659704
What this trial is testing

CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus

Who this might be right for
Lupus Erythematosus, Systemic
University of Sao Paulo 16
Next Page